文献速递前列腺癌

PARP抑制剂在转移性去势抵抗性前列腺癌中的应用:原理、机制与临床实践

PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.
PubMed 文献 · Eur Urol Oncol · 2025-11-11

本文综述PARP抑制剂(PARPi)治疗转移性去势抵抗性前列腺癌(mCRPC)的机制与临床证据。III期研究证实olaparib、niraparib、rucaparib和talazoparib可延长总生存(OS),尤其在BRCA1/2突变患者中。PARPi联合雄激素受体通路抑制剂(ARPI)可改善影像学无进展生存,talazoparib联合enzalutamide无论DNA修复基因突变状态均可改善OS。

要点

  • PARPi单药或联合ARPI已获批用于化疗不适用的mCRPC患者。
  • BRCA1/2、CDK12和PALB2突变患者从PARPi治疗中获益更大。
  • talazoparib联合enzalutamide无论突变状态均显示协同活性。

核心结论

  • PARPi单药或联合ARPI在mCRPC中显示生存获益,已获批准用于化疗不适用患者。
  • 患者选择与治疗序贯仍存疑问,需进一步研究。

研究设计与样本

  • 叙述性综述,回顾PARPi治疗CRPC的文献。

主要发现

  • III期研究证实olaparib、niraparib、rucaparib和talazoparib可延长OS,尤其在BRCA1/2突变患者中。
  • PARPi联合ARPI显示更长的影像学无进展生存,talazoparib联合enzalutamide无论DNA修复基因突变状态均改善OS。
  • PARPi应答因基因改变而异,BRCA1/2、CDK12和PALB2突变患者获益更大。

临床怎么用

  • PARPi单药或联合ARPI可用于化疗临床不适指的mCRPC患者,需考虑基因突变状态。

局限性

  • 患者选择与治疗序贯问题尚未解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND INTRODUCTION: Over the past 15 yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and, more recently, radium-223 radioligand therapy. However, metastatic PC is still the third leading cancer-related cause of death among men in Europe, with a 5-yr survival rate of ∼30% and median overall survival (OS) of <3 yr for castration-resistant PC (CRPC). Current strategies are moving towards personalised treatment, with the emergence of PARP inhibitors (PARPi) that exploit a vulnerability in the DNA repair system in patients with alterations in genes involved in homologous recombination. METHODS: We reviewed the literature on PARPi treatment for CRPC and provide a narrative synthesis of the evidence for the rapidly evolving treatment landscape in this setting. KEY FINDINGS AND LIMITATIONS: Phase 3 studies evaluating the efficacy of PARPi agents available (olaparib, niraparib, rucaparib, and talazoparib) for the treatment of metastatic CRPC have confirmed their ability to prolong OS, especially in patients carrying BRCA1/2 mutations. Studies on PARPi + ARPI combinations have shown longer radiological progression-free survival, and better OS with talazoparib + enzalutamide, regardless of mutational status for DNA repair genes, with synergistic activity identified. However, response to PARPi seems to vary depending on the genes altered, with a greater benefit for patients with mutations in genes encoding the repair effector proteins BRCA1/2, CDK12, and PALB2. CONCLUSIONS AND CLINICAL IMPLICATIONS: Promising results have led to the approval of several PARPi agents as monotherapy or in combination with ARPIs in selected or unselected patients when chemotherapy is not clinically indicated. However, some questions remain regarding patient selection and treatment sequencing.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Oudard S, Timsit MO, Maillet D, et al. PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications. Eur Urol Oncol. 2025. PMID: 41219112. doi:10.1016/j.euo.2025.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。